The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Rep. Mike Collins (R-Ga.) heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...